type-1 polarized dendritic cell-induced antigen-specific autologous cytotoxic T lymphocytes

{
  "id": "MLC-T-ONC-017374",
  "term": "type-1 polarized dendritic cell-induced antigen-specific autologous cytotoxic T lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous cytotoxic T lymphocytes (CTL), specifically reactive to melanoma-associated antigen 3 (MAGE-3), MAGE-4, survivin, human epidermal growth factor receptor 2 (HER2; ERBB2) and cyclooxygenase-2 (COX-2), with potential immunomodulating activity. Peripheral blood mononuclear cells (PBMCs) are collected from the patient. Subsequently, autologous dendritic cells (DCs) are separated, treated with a certain combination of cytokines to produce polarized type-1 DCs (DC1), and then are loaded with MAGE-3/MAGE-4/survivin/HER2/COX-2 CTL epitope peptides. In turn, autologous CTLs are collected, exposed ex vivo to the antigen-loaded DC1s and subsequently expanded in vitro. Upon re-infusion of the DC1-induced MAGE-3/MAGE-4/survivin/HER2/COX-2-specific autologous CTLs, the CTLs target and lyse tumor cells expressing the tumor-associated antigens (TAAs). Exposure to DC1s generates more potent CTLs and thus induces a more potent CTL response against TAA-expressing tumor cells. The targeted TAAs play key roles in cellular proliferation and are overexpressed by a variety of cancer cell types.",
  "abbreviation": "autologous DC1-CTL",
  "synonyms": [
    "type-1 polarized DC-induced antigen-specific autologous CTLs",
    "DC1-induced antigen-specific autologous CTLs"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/type-1-polarized-dendritic-cell-induced-antigen-specific-autologous-cytotoxic-t/"
}